Daval International Limited CSO Presents Results From an Exploratory Clinical Trial of AIMSPRO in Amyotrophic Lateral Sclerosis (ALS) at American Academy of Neurology Annual Meeting
3/21/2013 12:05:23 PM
More...
|
Daval International Limited Release: Results From an Exploratory Clinical Trial of AIMSPRO in Amyotrophic Lateral Sclerosis (ALS) to be Presented at AAN Annual Meeting
3/12/2013 10:11:06 AM
More...
|
Daval International Limited Announces Positive Phase II Results for AIMSPRO(R) as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
10/10/2011 7:01:22 AM
More...
|
Daval International Limited Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis
7/20/2011 10:50:22 AM
More...
|
Daval International Limited Awarded Orphan Drug Designation for Motor Neurone Disease Treatment
11/9/2009 8:58:23 AM
More...
|
Daval International Limited: AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis
6/1/2009 8:37:54 AM
More...
|
Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
11/26/2007 8:25:30 AM
More...
|